Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

Company's belief that the supplemental data to be submitted in the amended NDA will overcome the need for additional trials, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drugs Advisory Committee that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for L- MTP-PE, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Ph
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... held full service global investment bank specializing in ... industry note featuring Spherix. The report, ... Senior Analyst at Chardan, was published on March ...
(Date:4/1/2015)... 2015 Immunocore Limited ("the ... drugs to treat cancer, viral infections and autoimmune ... of Christina Coughlin as Chief Medical ... medical and regulatory leadership to the pre-clinical and ... Coughlin has extensive experience in oncology drug development, ...
(Date:3/31/2015)... March 31, 2015 Materials in ... ,   June 30 2015   Elsevier ... products and services and publishing home of Materials Today ... launched the Materials in Society  Lecture Series ... 8 th International Conference on Materials for Advanced ...
(Date:3/31/2015)... March 31, 2015  The Myeloma Crowd Research Initiative ... of ten proposals that will now be evaluated ... patient-led, scientifically validated funding initiative uncovering solutions for ... of the MCRI included preliminary vetting by the ... large number of innovative projects focusing on high-risk ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2
... , , SAN DIEGO, ... announced its financial results for the quarter ended June 30, 2009. For ... $15.3 million, or $0.39 per share, compared with a net loss of ... For the six months ended June 30, 2009, the Company reported a ...
... Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science ... Kielbania will appear on WVOX AM,s "In Focus" radio show on Wednesday ... The radio broadcast may be accessed via the Internet at ... Dan Miller , Dr. Miller is a retired school and college ...
... , , SOUTH SAN ... ) today reported financial results for the second quarter ended June 30, ... of 2009 was $3.5 million, with a net loss of $22.9 million, ... April. Loss from operations was $1.9 million for the second quarter and ...
Cached Biology Technology:Neurocrine Biosciences Reports Second Quarter 2009 Results 2Neurocrine Biosciences Reports Second Quarter 2009 Results 3Neurocrine Biosciences Reports Second Quarter 2009 Results 4Neurocrine Biosciences Reports Second Quarter 2009 Results 5Neurocrine Biosciences Reports Second Quarter 2009 Results 6Neurocrine Biosciences Reports Second Quarter 2009 Results 7BioNeutral Group's CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM 'In Focus' Radio Show Hosted by Dr. Dan Miller 2Sunesis Reports Financial Results for the Second Quarter 2009 2Sunesis Reports Financial Results for the Second Quarter 2009 3Sunesis Reports Financial Results for the Second Quarter 2009 4Sunesis Reports Financial Results for the Second Quarter 2009 5Sunesis Reports Financial Results for the Second Quarter 2009 6Sunesis Reports Financial Results for the Second Quarter 2009 7Sunesis Reports Financial Results for the Second Quarter 2009 8Sunesis Reports Financial Results for the Second Quarter 2009 9Sunesis Reports Financial Results for the Second Quarter 2009 10Sunesis Reports Financial Results for the Second Quarter 2009 11
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
(Date:3/12/2015)... IriTech, a leading iris based identity management ... Instruments Design Network, announced today that the Chief Minister ... USB MK2120U device during a launching event of Andhra ... The iris scanner is manufactured by U.S. ... India through its Indian partner, Biometronic ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Biology Products: